|Bid||0.00 x 2900|
|Ask||0.00 x 3200|
|Day's Range||5.01 - 5.14|
|52 Week Range||3.42 - 6.31|
|Beta (3Y Monthly)||2.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 2, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.08|
Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has sent a letter to fellow Progenics stockholders outlining the current Board’s failure to represent the best interests of stockholders, as most recently illustrated by the Company’s agreement to be acquired by Lantheus Medical Imaging, Inc. (“Lantheus”). The letter also highlights the Company’s recent misleading statements around Velan’s intentions and urges stockholders to consent to the replacement of three of the Company’s decade-plus tenured directors with Velan’s five highly-qualified, fully-independent nominees.
Calls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics’ WHITE Consent Revocation Card NEW.
Plan Highlights Nominees’ Skill Sets and Expertise that Velan Believes Would Lead to Improvements in Company’s Culture, Operational Execution, Financial Standing, Governance, Leade
NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Proteon Therapeutics, Inc. (NASDAQ:PRTO ) The investigation ...
WILMINGTON, Del., Oct. 17, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible breaches.
NEW YORK, Oct. 15, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ra Pharmaceuticals, Inc. (NASDAQ: RARX)The.
Progenics Pharmaceuticals, Inc. Pushed Through Questionable Merger with Votes from Directors Who Had Resigned Progenics Agreed to Large Termination Fee in Possible Move to Trap Shareholders in Deal Corporate Governance Expert Finds Termination Fee, Lame Duck Director Votes “Troubling” Stock Trading Above Offer Price, Suggesting Shareholders Want A Kiss or Deal Scrapped By John […]
BALA CYNWYD, PA / ACCESSWIRE / October 11, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Progenics Pharmaceuticals, Inc. ...
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
NEW YORK, Oct. 08, 2019 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice.
NEW YORK , Oct. 8, 2019 /PRNewswire/ -- Arotech Corporation (ARTX) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Arotech to Greenbriar ...
Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has sent a letter to fellow Progenics stockholders and filed a definitive consent statement with the Securities and Exchange Commission in connection with its solicitation of written consents from stockholders to reconstitute the Progenics Board of Directors through the removal of the three long-tenured directors and the election of five new, highly-qualified, fully-independent nominees.
NEW YORK , Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc. ("Progenics" ...
Merger and Acquisition activity, or M&A, is at multi-year lows. Transaction volume has dried up thanks to business uncertainty around tariffs, trade tensions and increasing worries about the prospects for global growth, amid many other factors. On Wednesday, Lantheus Holdings announced it reached a deal to acquired Progenics Pharmaceuticals in an all-stock transaction.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Progenics Pharmaceuticals, Inc.
WILMINGTON, Del., Oct. 03, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Highlands Bankshares, Inc. (OTC Pink: HLND) regarding possible breaches of.
Chardan Heathcare Acquisition Corp. (CHAC) related to its combination with BiomX Ltd. Pursuant to the terms of the Merger Agreement, BiomX's securityholders will receive an aggregate of 16,625,000 Chardan shares. As a result of the Proposed Transaction, Chardan's public stockholders will only own approximately 20% of Chardan's stock. Click here for more information: https://www.monteverdelaw.com/case/chardan-healthcare-acquisition-corp. It is free and there is no cost or obligation to you. Restoration Robotics, Inc (HAIR) related to its combination with Venus Concept Ltd. Pursuant to the terms of the Merger Agreement, each share of Venus Concept will be converted into the right to receive 8.6506 shares of Restoration Robotics common stock.
MILWAUKEE , Oct. 3, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale ...
NEW YORK, Oct. 03, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Progenics Pharmaceuticals, Inc..
NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on behalf of Progenics ...
Micro-cap biotech Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ) is advancing strongly following an announcement concerning a buyout deal. The Deal Lantheus Holdings Inc (NASDAQ: LNTH ) and Progenics, ...
NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and its board of directors for breach of fiduciary duty ...
Believes Company’s Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard